Skip to main content
. 2020 Apr 2;135(21):1847–1858. doi: 10.1182/blood.2019003858

Table 4.

Multivariable logistic regression for risks of symptom domain prevalence and poor HRQOL between overall HSCT and conventional therapy survivors by accounting for chronic health conditions

Risk factors Sensationabnormalities Motor/movementproblems Cardiacsymptoms Pulmonarysymptoms Pain Fatigue
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Treatment group
 Overall HSCT vs conventional therapy survivors* 1.2 (0.8-2.0) 1.0 (0.5-1.9) 0.9 (0.4-1.7) 1.0 (0.5-1.9) 0.5 (0.3-0.8) 0.7 (0.3-1.3)
Age at survey 1.1 (1.0-1.1) 1.1 (1.0-1.1) 1.1 (1.0-1.1) 1.1 (1.0-1.1) 1.0 (1.0- 1.1) 1.1 (1.0-1.1)
Sex
 Female vs male* 1.3 (1.1-1.7) 1.5 (1.0-2.1) 2.4 (1.7-3.5) 1.5 (1.0-2.0) 1.7 (1.3-2.3) 1.9 (1.4-2.5)
Race/ethnicity
 White, non-Hispanic vs other* 1.4 (1.0-2.0) 1.0 (0.6-1.5) 0.9 (0.6-1.4) 0.8 (0.5-1.2) 1.3 (0.9-1.8) 1.1 (0.7-1.7)
Education
 <College vs ≥college* 1.3 (1.0-1.8) 1.7 (1.2-2.6) 1.5 (1.1-2.3) 1.6 (1.1-2.3) 1.8 (1.3-2.4) 2.3 (1.6-3.3)
Marital status
 Single/divorced/other vs married/living with partner* 1.0 (0.8-1.4) 1.6 (1.1-2.3) 1.0 (0.7-1.4) 1.7 (1.2-2.4) 0.8 (0.6-1.1) 0.9 (0.7-1.3)
Cardiovascular 1.3 (0.8-1.9) 1.2 (0.7-2.1) 3.0 (1.8-4.9) 1.2 (0.7-2.1) 1.5 (0.9-2.7) 1.2 (0.7-2.0)
Endocrine 1.4 (1.1-1.8) 1.9 (1.4-2.7) 1.0 (0.7-1.4) 1.2 (0.9-1.8) 1.4 (1.0-1.8) 1.5 (1.1-2.1)
Gastrointestinal 1.3 (0.9-1.9) 1.4 (0.9-2.3) 1.2 (0.7-2.0) 1.5 (0.9-2.4) 1.3 (0.8-2.1) 1.2 (0.7-1.9)
Neurology 1.9 (1.2-3.1) 3.3 (2.0-5.5) 1.4 (0.8-2.5) 1.9 (1.1-3.2) 1.3 (0.8-2.4) 1.9 (1.2-3.2)
Ocular 2.2 (1.0-4.8) 2.7 (1.1-6.9) 1.0 (0.3-2.9) 0.5 (0.1-1.7) 2.3 (0.9-6.0) 2.3 (0.9-5.6)
Pulmonary 1.0 (0.6-1.7) 0.9 (0.4-1.7) 3.0 (1.7-5.3) 2.5 (1.4-4.3) 1.8 (0.9-3.6) 1.0 (0.5-1.8)
Reproductive 1.3 (1.0-1.8) 0.8 (0.5-1.2) 0.9 (0.6-1.4) 1.0 (0.6-1.5) 1.4 (1.0-2.0) 1.4 (1.0-2.1)
Risk factors Nausea Memory problems Anxiety Depression PCS (score ≤40) MCS (score ≤40)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Treatment group
 Overall HSCT vs conventional therapy survivors* 0.8 (0.4-1.6) 1.2 (0.8-2.1) 0.8 (0.5-1.4) 0.7 (0.4-1.2) 1.0 (0.5-2.0) 0.8 (0.5-1.5)
Age at survey 1.0 (1.0-1.0) 1.0 (0.9-1.0) 1.0 (1.0-1.1) 1.1 (1.0-1.1) 1.1 (1.1-1.1) 1.1 (1.0-1.1)
Sex
 Female vs male* 1.9 (1.4-2.7) 1.5 (1.2-2.0) 1.3 (1.1-1.7) 1.3 (1.0-1.6) 1.5 (1.0-2.1) 1.5 (1.1-2.0)
Race/ethnicity
 White, non-Hispanic vs other* 1.1 (0.7-1.7) 1.8 (1.2-2.6) 1.1 (0.8-1.6) 0.9 (0.7-1.3) 1.0 (0.6-1.5) 1.1 (0.7-1.5)
Education
 <College vs ≥college* 1.4 (1.0-2.0) 2.1 (1.5-2.8) 1.3 (1.0-1.7) 1.5 (1.1-2.0) 2.6 (1.7-4.0) 2.1 (1.5-3.0)
Marital status
 Single/divorced/other vs married/living with partner* 0.9 (0.6-1.3) 1.5 (1.1-2.0) 1.3 (1.0-1.7) 2.0 (1.5-2.6) 1.4 (0.9-2.0) 1.6 (1.2-2.2)
Cardiovascular 1.2 (0.7-2.0) 0.9 (0.6-1.5) 1.1 (0.7-1.7) 1.6 (1.0-2.4) 2.8 (1.7-4.6) 1.6 (1.0-2.5)
Endocrine 1.6 (1.1-2.3) 1.2 (0.9-1.6) 1.1 (0.9-1.4) 1.4 (1.1-1.9) 1.3 (0.9-1.9) 1.4 (1.0-1.8)
Gastrointestinal 2.0 (1.2-3.1) 1.1 (0.7-1.7) 1.4 (1.0-2.1) 1.3 (0.9-1.9) 1.3 (0.8-2.1) 0.9 (0.6-1.4)
Neurology 1.2 (0.6-2.2) 2.2 (1.4-3.5) 1.0 (0.6-1.6) 1.3 (0.8-2.1) 2.6 (1.6-4.4) 1.6 (1.0-2.6)
Ocular 1.6 (0.6-4.2) 0.7 (0.3-1.7) 0.7 (0.3-1.6) 0.6 (0.2-1.5) 2.1 (0.8-5.4) 0.9 (0.3-2.2)
Pulmonary 1.5 (0.8-2.7) 2.0 (1.2-3.3) 1.0 (0.6-1.7) 1.1 (0.6-1.9) 2.7 (1.6-4.8) 1.5 (0.9-2.6)
Reproductive 1.5 (1.0-2.2) 1.1 (0.8-1.6) 1.1 (0.8-1.5) 1.2 (0.9-1.7) 1.3 (0.9-1.9) 0.9 (0.6-1.3)
*

Reference group.

CTCAE grades 3-4 vs none or 1-2.